Skip to main content
. 2016 Apr 18;113(19):E2646–E2654. doi: 10.1073/pnas.1604268113

Fig. 2.

Fig. 2.

Anti-mouse CD47 antagonist nanobody enhances macrophage-mediated ADCP. (A) Representative histograms of B16-F10 cell surface CD47, TRP-1, and CD200 expression determined by flow cytometry. (B) Antibody-dependent phagocytosis of B16-F10 cells by bone marrow-derived C57BL/6J mouse macrophages treated with various combinations of control (αCD200) or tumor antigen-specific (αTRP-1) antibody with or without CD47 antagonist nanobody (A4). Phagocytosis is quantified as the percentage of F4/80-positive macrophages that have engulfed CFSE-positive B16-F10 cells as depicted in the representative FACS plots. (C) Representative histograms of Tubo-EGFR cell surface CD200, CD47, and human EGFR (hEGFR) expression determined by flow cytometry. (D) Antibody-dependent phagocytosis of Tubo-EGFR cells by bone marrow-derived BALB/c macrophages as described in B. The data shown are the mean (n = 3), and error bars indicate SD. ****P < 0.0001 determined by one-way analysis of variance test in Prism.